Related Experiment Video
Updated: Jan 23, 2026

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression
Published on: March 17, 2020
CELF2 suppresses non-small cell lung carcinoma growth by inhibiting the PREX2-PTEN interaction
Yiu To Yeung1,2, Suyu Fan1, Bingbing Lu1,3
1The China-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China.
Abstract:
The phosphoinositide 3-kinase (PI3-K)/Akt signaling pathway is important in the regulation of cell proliferation through its production of phosphatidylinositol 3,4,5-triphosphate (PIP3). Activation of this pathway is frequently observed in human cancers, including non-small cell lung carcinoma. The PI3-K/Akt pathway is negatively regulated by the dual-specificity phosphatase and tensin homolog (PTEN) protein. PTEN acts as a direct antagonist of PI3-K by dephosphorylating PIP3. Studies have shown that PTEN phosphatase activity is inhibited by PREX2, a guanine nucleotide exchanger factor (GEF). Multiple studies revealed that CELF2, an RNA binding protein, cooperates synergistically with PTEN as a tumor suppressor in multiple cancers. However, the underlying mechanism as to how CELF2 enhances PTEN activity remains unclear. Here, we report that CELF2 interacts with PREX2 and reduces the association of PREX2 with PTEN. Consistent with this observation, PTEN phosphatase activity is upregulated with CELF2 overexpression. In addition, overexpression of CELF2 represses both Akt phosphorylation and cell proliferation only in the presence of PTEN. In an ex vivo study, CELF2 gene delivery could significantly inhibit patient-derived xenografts (PDX) tumor growth. To further investigate the clinical relevance of this finding, we analyzed 87 paired clinical lung adenocarcinoma samples and the results showed that CELF2 protein expression is downregulated in tumor tissues and associated with poor prognosis. The CELF2 gene is located on the chromosome 10p arm, a region frequently lost in human cancers, including breast invasive carcinoma, low-grade glioma and glioblastoma. Analysis of TCGA datasets showed that CELF2 expression is also associated with shorter patient survival time in all these cancers. Overall, our work suggests that CELF2 plays a novel role in PI3-K signaling by antagonizing the oncogenic effect of PREX2.
Insights
CELF2 enhances tumor suppression by interacting with PREX2, thereby increasing PTEN activity. This mechanism inhibits cancer cell proliferation and improves patient prognosis, particularly in lung adenocarcinoma.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The phosphoinositide 3-kinase (PI3-K)/Akt pathway regulates cell proliferation and is often dysregulated in cancers.
- PTEN protein negatively regulates the PI3-K/Akt pathway by dephosphorylating PIP3.
- PREX2 inhibits PTEN activity, while CELF2 is known to act as a tumor suppressor, but its mechanism with PTEN is unclear.
Purpose of the Study:
- To elucidate the mechanism by which CELF2 enhances PTEN tumor suppressor activity.
- To investigate the role of CELF2 in regulating the PI3-K/Akt pathway and cancer cell proliferation.
- To assess the clinical relevance of CELF2 in lung adenocarcinoma and other cancers.
Main Methods:
- Investigated the interaction between CELF2 and PREX2 using biochemical assays.
- Assessed PTEN phosphatase activity upon CELF2 overexpression.
- Evaluated the effect of CELF2 on Akt phosphorylation and cell proliferation in vitro.
- Performed ex vivo studies using patient-derived xenografts (PDX) with CELF2 gene delivery.
- Analyzed CELF2 protein expression and its correlation with prognosis in clinical lung adenocarcinoma samples.
- Examined CELF2 gene location and expression patterns in The Cancer Genome Atlas (TCGA) datasets for various cancers.
Main Results:
- CELF2 directly interacts with PREX2, reducing PREX2's association with PTEN.
- CELF2 overexpression leads to upregulated PTEN phosphatase activity.
- Overexpression of CELF2 inhibits Akt phosphorylation and cell proliferation, dependent on PTEN presence.
- CELF2 gene delivery significantly inhibited PDX tumor growth.
- CELF2 protein expression is downregulated in lung adenocarcinoma tissues and correlates with poor prognosis.
- CELF2 expression is associated with shorter survival times in multiple cancers, including breast invasive carcinoma, low-grade glioma, and glioblastoma.
Conclusions:
- CELF2 antagonizes the oncogenic effect of PREX2 by disrupting the PREX2-PTEN interaction, thereby enhancing PTEN tumor suppressor function.
- CELF2 acts as a novel regulator of the PI3-K/Akt signaling pathway.
- CELF2 downregulation in tumors suggests its potential as a prognostic biomarker and therapeutic target in various cancers.
Related Concept Videos
Feedback Inhibition
Lung Capacity
Enzyme Inhibition
Primary and Secondary Growth in Roots and Shoots
Cells Coordinate Growth and Proliferation
Population Growth

